Celgene Profit Beats Forecasts as Revlimid Delivers

Celgene's quarterly earnings rose 14%, beating expectations, on strong sales of its Revlimid cancer treatment and lower costs, and the biotechnology company narrowly raised its full-year profit forecast.

The company said on Thursday it earned $424 million, or 97 cents per share, in the third quarter, compared with $373 million, or 81 cents per share, in the year-earlier period.

Excluding special items, Celgene earned $1.29 per share. Analysts, on average, had expected $1.27, according to Thomson Reuters I/B/E/S.

Revenue rose 14% to $1.42 billion, topping Wall Street expectations of $1.41 billion.

Revlimid, a treatment for multiple myeloma, is Celgene's biggest product and profit driver. Sales of the drug jumped 18% to $970 million, in line with Wall Street forecasts. The growth was fueled by patient use of the drug earlier and over longer time frames, and introduction of the medicine in new regions.

But sales of Abraxane, a treatment for metastatic breast cancer, fell 6% to $106 million. Celgene said the decline was partly due to a surge in U.S. demand for the drug in 2011 as a result of shortages of standard chemotherapy agent paclitaxel.

Sales of Vidaza, used to treat a group of blood disorders known as myelodysplastic syndromes, rose 15% to $220 million. Sales of Thalomid, the company's older treatment for multiple myeloma, fell 10% to $75 million.

The company boosted its 2012 earnings forecast, excluding special items, to between $4.85 and $4.90 per share, from a previous view of $4.80 to $4.85.

Celgene said it expects full-year Revlimid sales to rise about 18% to between $3.75 and $3.8 billion. It previously forecast $3.75 billion to $3.85 billion.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.